David Hoffmeister, last week named new chief financial officer for Invitrogen, will earn a base salary of $425,000 plus an incentive bonus, guaranteed for his first year, and a one-time signing bonus of $375,000, the company said this week in an 8-K filing with the US Securities and Exchange Commission. Hoffmeister will also receive a $224,000 employment bonus payable on or before each of the first three anniversary dates of his employment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.